California Senate gives nod to biosimilar interchangeable bill
This article was originally published in SRA
Executive Summary
Amgen's and Genentech's lobbying paid off on 4 September when senators from the US biotech giants' home state of California gave their blessing to legislation that would require pharmacists to notify prescribers within five days of the pharmacy substituting a biosimilar deemed interchangeable by the Food and Drug Administration for an innovator biologic.